Document Format Files
| Seq | Description | Document | Type | Size |
|---|---|---|---|---|
| 1 | F-1/A | tm2415654-14_f1a.htm | F-1/A | 8057631 |
| 2 | EXHIBIT 1.1 | tm2415654d15_ex1-1.htm | EX-1.1 | 320093 |
| 3 | EXHIBIT 5.1 | tm2415654d15_ex5-1.htm | EX-5.1 | 31270 |
| 4 | EXHIBIT 8.2 | tm2415654d15_ex8-2.htm | EX-8.2 | 44609 |
| 5 | EXHIBIT 23.1 | tm2415654d15_ex23-1.htm | EX-23.1 | 1945 |
| 6 | EXHIBIT 99.2 | tm2415654d15_ex99-2.htm | EX-99.2 | 5731 |
| 7 | EXHIBIT 99.3 | tm2415654d15_ex99-3.htm | EX-99.3 | 10754 |
| 8 | EX-FILING FEES | tm2415654d15_ex-filingfees.htm | EX-FILING FEES | 14634 |
| 9 | GRAPHIC | lg_ascentagepharma-4clr.jpg | GRAPHIC | 26109 |
| 10 | GRAPHIC | fc_compunds-4c.jpg | GRAPHIC | 67294 |
| 11 | GRAPHIC | fc_summary-4c.jpg | GRAPHIC | 85642 |
| 12 | GRAPHIC | fc_cashflows-4c.jpg | GRAPHIC | 137590 |
| 13 | GRAPHIC | tm2415654d15_ex8-2img001.jpg | GRAPHIC | 38433 |
| 14 | GRAPHIC | fc_olverembatinib-4c.jpg | GRAPHIC | 70059 |
| 15 | GRAPHIC | ph_mechanism-4clr.jpg | GRAPHIC | 86748 |
| 16 | GRAPHIC | tb_mutations-4c.jpg | GRAPHIC | 172150 |
| 17 | GRAPHIC | lc_cumulative-4c.jpg | GRAPHIC | 58472 |
| 18 | GRAPHIC | lc_patients-4clr.jpg | GRAPHIC | 33505 |
| 19 | GRAPHIC | bc_decreasing-4c.jpg | GRAPHIC | 42665 |
| 20 | GRAPHIC | lc_eventfreesurvival-4clr.jpg | GRAPHIC | 43902 |
| 21 | GRAPHIC | bc_monotherapy-4c.jpg | GRAPHIC | 44428 |
| 22 | GRAPHIC | bc_response-4c.jpg | GRAPHIC | 58247 |
| 23 | GRAPHIC | bc_molecular-4clr.jpg | GRAPHIC | 30684 |
| 24 | GRAPHIC | bc_threemonths-4clr.jpg | GRAPHIC | 18698 |
| 25 | GRAPHIC | lc_median-4clr.jpg | GRAPHIC | 29321 |
| 26 | GRAPHIC | fc_regtrials-4c.jpg | GRAPHIC | 32676 |
| 27 | GRAPHIC | fc_polaris1-4c.jpg | GRAPHIC | 36116 |
| 28 | GRAPHIC | fc_polaris2-4clr.jpg | GRAPHIC | 75757 |
| 29 | GRAPHIC | fc_lisaftoclax-4c.jpg | GRAPHIC | 74410 |
| 30 | GRAPHIC | ph_apoptosome-4clr.jpg | GRAPHIC | 67653 |
| 31 | GRAPHIC | lc_bestoverallres-4c.jpg | GRAPHIC | 101661 |
| 32 | GRAPHIC | fc_dialydose-4c.jpg | GRAPHIC | 41058 |
| 33 | GRAPHIC | tb_combination-4c.jpg | GRAPHIC | 34939 |
| 34 | GRAPHIC | bc_efficacyreports-4c.jpg | GRAPHIC | 58652 |
| 35 | GRAPHIC | tb_amlpatients-4c.jpg | GRAPHIC | 53450 |
| 36 | GRAPHIC | tb_safetyresults-4c.jpg | GRAPHIC | 73591 |
| 37 | GRAPHIC | tb_44patiens-4c.jpg | GRAPHIC | 87495 |
| 38 | GRAPHIC | bc_synergistic-4clr.jpg | GRAPHIC | 136267 |
| 39 | GRAPHIC | fc_lisareggrials-4c.jpg | GRAPHIC | 54142 |
| 40 | GRAPHIC | fc_glora-4c.jpg | GRAPHIC | 51050 |
| 41 | GRAPHIC | fc_glora2-4c.jpg | GRAPHIC | 50245 |
| 42 | GRAPHIC | fc_glora3-4c.jpg | GRAPHIC | 55327 |
| 43 | GRAPHIC | fc_candidates-4c.jpg | GRAPHIC | 31832 |
| 44 | GRAPHIC | ph_alrizomadlin-4clr.jpg | GRAPHIC | 121607 |
| 45 | GRAPHIC | fc_carcinoma-4c.jpg | GRAPHIC | 79032 |
| 46 | GRAPHIC | bc_selectclinical-4c.jpg | GRAPHIC | 58026 |
| 47 | GRAPHIC | ph_anemia-4clr.jpg | GRAPHIC | 73637 |
| Complete submission text file | 0001104659-25-004650.txt | 11884640 |
EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: F-1/A | Act: 33 | File No.: 333-284064 | Film No.: 25540290
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)
